{"protocolSection": {"identificationModule": {"nctId": "NCT02968914", "orgStudyIdInfo": {"id": "D3250C00030"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers", "officialTitle": "A Multicenter, Randomized, Open-Label, Parallel Group Phase 1 Pharmacokinetic Comparability Study of Benralizumab Administrated Using Accessorized Pre-Filled Syringe (APFS) or Autoinjector (AI) in Healthy Volunteers."}, "statusModule": {"statusVerifiedDate": "2019-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-01-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-07-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-07-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-10-28", "studyFirstSubmitQcDate": "2016-11-17", "studyFirstPostDateStruct": {"date": "2016-11-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-01-02", "resultsFirstSubmitQcDate": "2019-07-03", "resultsFirstPostDateStruct": {"date": "2019-07-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-07-03", "lastUpdatePostDateStruct": {"date": "2019-07-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Parexel", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI) devices.", "detailedDescription": "A study of descriptive comparison of benralizumab PK by weight and injection site.\n\nThis study will be a multicenter, randomized, open-label, parallel group Phase 1 study designed to compare benralizumab PK exposure in healthy subjects following single subcutaneous (SC) administration of fixed 30 mg dose of benralizumab by using APFS and single-use AI. Eligible subjects will be healthy subjects aged 18 to 55 years, with a body weight of 55 to 100 kg and a body mass index of 18 to 29.9 kg/m2 . A total of 180 subjects will be randomized. Randomization will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg), and within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS or AI) with injection site (upper arm, abdomen or thigh), presented in Table 1. This study will be performed at 2 study centers."}, "conditionsModule": {"conditions": ["Asthma", "Chronic Obstructive Pulmonary Disease"], "keywords": ["Asthma", "Chronic Obstructive pulmonary Disease", "Pharmacokinetics", "Healthy volunteers"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 180, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab by Accessorized Pre-Filled Syringe", "type": "ACTIVE_COMPARATOR", "description": "Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Benralizumab by Autoinjector", "type": "OTHER", "description": "Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)", "interventionNames": ["Biological: Benralizumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5R\u03b1) on the target cell.", "armGroupLabels": ["Benralizumab by Accessorized Pre-Filled Syringe"]}, {"type": "BIOLOGICAL", "name": "Benralizumab", "description": "A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5R\u03b1) on the target cell.", "armGroupLabels": ["Benralizumab by Autoinjector"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)", "description": "To compare the AUCinf following single SC administration of Benralizumab by using APFS or AI devices", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)", "description": "To compare the AUClast following single SC administration of Benralizumab by using APFS or AI devices", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Maximum Observed Concentration (Cmax)", "description": "To compare the Cmax following single SC administration of Benralizumab by using APFS or AI devices", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}], "secondaryOutcomes": [{"measure": "Time When Maximum Concentration is Observed (Tmax)", "description": "To evaluate the Tmax of Benralizumab administered to various injection sites and in subjects with different body weight ranges", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Terminal Half-life (t\u00bd)", "description": "To evaluate the t\u00bd of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Apparent Extravascular Clearance (CL/F)", "description": "To evaluate the CL/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Apparent Volume of Distribution Based on the Terminal Phase (Vz/F)", "description": "To evaluate the Vz/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Number of Participants With Adverse Events", "description": "To evaluate safety and tolerability of Benralizumab", "timeFrame": "At predose and 2 h postdose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57"}, {"measure": "Antidrug Antibody (ADA) Status", "description": "To evaluate the immunogenicity of Benralizumab", "timeFrame": "At predose (Day 1), Days 29 and 57"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and/or female subjects of non-child-bearing potential aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.\n* Females must be non pregnant,non lactating and non-child-bearing potential, confirmed at screening\n* Sexually active male willingness to use contraception\n* Body mass index (BMI) between 18 and 29.9 kg/m2 inclusive and weigh at least 55 kg and no more than 100 kg inclusive.\n\nExclusion Criteria:\n\n* History of any clinically significant disease, severe allergy/anaphylaxis to any biologic therapy, Guillain-Barr\u00e9 syndrome, smoking and alcohol or drug abuse\n* Diagnosis of helminth parasitic infection and acute upper or lower respiratory infections\n* Disorders related to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment\n* Alanine aminotransferase/aspartate aminotransferase level \u22651.5 times the upper limit of normal\n* White blood cell count and neutrophils \\< lower limit of normal\n* Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of Investigational medicinal product (IMP)\n* Positive result for serum hepatitis B surface antigen or anti-Hemoglobin C (anti-HBc) antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.\n* Intake of new chemical entity (not been approved for marketing) within 3 months of the first administration of investigational product\n* Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening\n* Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent\n* Receipt of any marketed (e.g., omalizumab, mepolizumab etc.) or investigational biologic within 4 months or 5 half-lives prior to the date informed consent\n* Receipt of live attenuated vaccines 30 days prior to randomization on Day 1\n* Current malignancy, or history of malignancy except (basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix)\n* Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.\n* Use of antacids, analgesics (except paracetamol/acetaminophen), herbal remedies, mega-dose vitamins (20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer\n* Previous receipt of received benralizumab\n* Any ongoing or recent minor medical complaints\n* Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dr. Rainard Fuhr, Medicine", "affiliation": "PAREXEL Early Phase Clinical Unit Berlin", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Dr. Pablo Forte-Soto", "affiliation": "PAREXEL Early Phase Clinical Unit London", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Berlin", "zip": "14050", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Harrow", "zip": "HA1 3UJ", "country": "Germany"}]}, "referencesModule": {"references": [{"pmid": "31539289", "type": "DERIVED", "citation": "Martin UJ, Fuhr R, Forte P, Barker P, Axley MJ, Aurivillius M, Yan L, Roskos L. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J Asthma. 2021 Jan;58(1):93-101. doi: 10.1080/02770903.2019.1663428. Epub 2019 Sep 20."}], "seeAlsoLinks": [{"label": "SAP", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4091&filename=230172_D3250C00030_SAP_Final_21-Sep-2018.pdf"}, {"label": "SP", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4091&filename=230172_D3250C00030_Protocol_Final_21-Sep-2018.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects attended a Screening Visit within 28 days before receiving their first dose of Benralizumab. All subjects underwent inclusion exclusion criteria assessment and all eligible subjects signed the informed consent before undergoing any study-related procedures.", "recruitmentDetails": "Subjects who met all the inclusion and none of the exclusion criteria were enrolled at PAREXEL Early Phase Clinical Unit in Berlin and London.", "groups": [{"id": "FG000", "title": "Benralizumab 30mg Autoinjector (AI)", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "FG001", "title": "Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "90"}, {"groupId": "FG001", "numSubjects": "90"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "90"}, {"groupId": "FG001", "numSubjects": "90"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benralizumab 30mg Autoinjector (AI)", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "BG001", "title": "Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "180"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.8", "spread": "10.8"}, {"groupId": "BG001", "value": "41.1", "spread": "11.1"}, {"groupId": "BG002", "value": "40.9", "spread": "10.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "33"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "147"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "177"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "163"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)", "description": "To compare the AUCinf following single SC administration of Benralizumab by using APFS or AI devices", "populationDescription": "The PK analysis set consisted of all subjects who received benralizumab for whom PK blood samples were assumed not to be affected by factors such as protocol violations (e.g., disallowed medications or incomplete dose administration) and who had at least one post dose quantifiable serum PK observation.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "day\u00b7ng/mL", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "87"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "72210", "spread": "29.7"}, {"groupId": "OG001", "value": "76220", "spread": "32.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "statisticalMethod": "ANOVA", "paramType": "Geometric mean ratio (%)", "paramValue": "94.46", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "88.16", "ciUpperLimit": "101.21"}]}, {"type": "PRIMARY", "title": "Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)", "description": "To compare the AUClast following single SC administration of Benralizumab by using APFS or AI devices", "populationDescription": "The PK analysis set consisted of all subjects who received benralizumab for whom PK blood samples were assumed not to be affected by factors such as protocol violations (e.g., disallowed medications or incomplete dose administration) and who had at least one post dose quantifiable serum PK observation.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "day\u00b7ng/mL", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "60560", "spread": "27.3"}, {"groupId": "OG001", "value": "65230", "spread": "29.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "statisticalMethod": "ANOVA", "paramType": "Geometric mean ratio (%)", "paramValue": "92.83", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "87.41", "ciUpperLimit": "98.58"}]}, {"type": "PRIMARY", "title": "Maximum Observed Concentration (Cmax)", "description": "To compare the Cmax following single SC administration of Benralizumab by using APFS or AI devices", "populationDescription": "The PK analysis set consisted of all subjects who received benralizumab for whom PK blood samples were assumed not to be affected by factors such as protocol violations (e.g., disallowed medications or incomplete dose administration) and who had at least one post dose quantifiable serum PK observation.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2096", "spread": "32.7"}, {"groupId": "OG001", "value": "2269", "spread": "35.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "statisticalMethod": "ANOVA", "paramType": "Geometric mean ratio (%)", "paramValue": "92.34", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "86.34", "ciUpperLimit": "98.75"}]}, {"type": "SECONDARY", "title": "Time When Maximum Concentration is Observed (Tmax)", "description": "To evaluate the Tmax of Benralizumab administered to various injection sites and in subjects with different body weight ranges", "populationDescription": "The PK analysis set consisted of all subjects who received benralizumab for whom PK blood samples were assumed not to be affected by factors such as protocol violations (e.g., disallowed medications or incomplete dose administration) and who had at least one post dose quantifiable serum PK observation.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Days", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"title": "Abdomen 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.59", "lowerLimit": "2.97", "upperLimit": "7.04"}, {"groupId": "OG001", "value": "6.06", "lowerLimit": "4.00", "upperLimit": "14.00"}]}]}, {"title": "Abdomen 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.98", "lowerLimit": "3.98", "upperLimit": "14.00"}, {"groupId": "OG001", "value": "5.98", "lowerLimit": "2.95", "upperLimit": "14.05"}]}]}, {"title": "Abdomen 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.06", "lowerLimit": "3.95", "upperLimit": "7.11"}, {"groupId": "OG001", "value": "6.96", "lowerLimit": "3.99", "upperLimit": "7.10"}]}]}, {"title": "Thigh 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.00", "lowerLimit": "2.97", "upperLimit": "7.01"}, {"groupId": "OG001", "value": "4.52", "lowerLimit": "2.94", "upperLimit": "7.04"}]}]}, {"title": "Thigh 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.05", "lowerLimit": "2.98", "upperLimit": "6.90"}, {"groupId": "OG001", "value": "3.52", "lowerLimit": "2.95", "upperLimit": "7.12"}]}]}, {"title": "Thigh 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.59", "lowerLimit": "2.94", "upperLimit": "13.95"}, {"groupId": "OG001", "value": "4.03", "lowerLimit": "2.98", "upperLimit": "6.98"}]}]}, {"title": "Upper arm 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.97", "lowerLimit": "3.97", "upperLimit": "14.02"}, {"groupId": "OG001", "value": "4.96", "lowerLimit": "3.02", "upperLimit": "14.04"}]}]}, {"title": "Upper arm 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.00", "lowerLimit": "5.01", "upperLimit": "14.03"}, {"groupId": "OG001", "value": "5.02", "lowerLimit": "2.99", "upperLimit": "8.01"}]}]}, {"title": "Upper arm 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.00", "lowerLimit": "3.09", "upperLimit": "14.03"}, {"groupId": "OG001", "value": "6.97", "lowerLimit": "1.02", "upperLimit": "14.13"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Half-life (t\u00bd)", "description": "To evaluate the t\u00bd of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.", "populationDescription": "The PK analysis set consisted of all the subjects as defined for above endpoint. For Benralizumab 30mg AI, two subjects and for Benralizumab 30mg AFPS, three subjects were excluded from the PK analysis set.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Days", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "87"}]}], "classes": [{"title": "Abdomen 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.83", "spread": "24.9"}, {"groupId": "OG001", "value": "20.15", "spread": "21.8"}]}]}, {"title": "Abdomen 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.22", "spread": "21.0"}, {"groupId": "OG001", "value": "17.43", "spread": "21.7"}]}]}, {"title": "Abdomen 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.59", "spread": "19.9"}, {"groupId": "OG001", "value": "21.04", "spread": "21.7"}]}]}, {"title": "Thigh 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.58", "spread": "20.6"}, {"groupId": "OG001", "value": "19.72", "spread": "21.4"}]}]}, {"title": "Thigh 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.93", "spread": "23.4"}, {"groupId": "OG001", "value": "18.28", "spread": "17.9"}]}]}, {"title": "Thigh 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.02", "spread": "19.9"}, {"groupId": "OG001", "value": "17.30", "spread": "11.5"}]}]}, {"title": "Upper arm 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.46", "spread": "13.6"}, {"groupId": "OG001", "value": "17.30", "spread": "26.9"}]}]}, {"title": "Upper arm 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.54", "spread": "14.0"}, {"groupId": "OG001", "value": "20.16", "spread": "25.3"}]}]}, {"title": "Upper arm 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.01", "spread": "26.9"}, {"groupId": "OG001", "value": "19.42", "spread": "26.3"}]}]}]}, {"type": "SECONDARY", "title": "Apparent Extravascular Clearance (CL/F)", "description": "To evaluate the CL/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.", "populationDescription": "The PK analysis set consisted of all the subjects as defined for above endpoint. For Benralizumab 30mg AI, two subjects and for Benralizumab 30mg AFPS, three subjects were excluded from the PK analysis set.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "mL/day", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "87"}]}], "classes": [{"title": "Abdomen 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "388.8", "spread": "34.3"}, {"groupId": "OG001", "value": "388.9", "spread": "43.8"}]}]}, {"title": "Abdomen 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "462.9", "spread": "29.5"}, {"groupId": "OG001", "value": "508.9", "spread": "33.2"}]}]}, {"title": "Abdomen 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "504.6", "spread": "18.3"}, {"groupId": "OG001", "value": "402.7", "spread": "30.4"}]}]}, {"title": "Thigh 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "350.1", "spread": "32.6"}, {"groupId": "OG001", "value": "281.1", "spread": "16.8"}]}]}, {"title": "Thigh 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "393.7", "spread": "29.6"}, {"groupId": "OG001", "value": "325.9", "spread": "18.2"}]}]}, {"title": "Thigh 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "378.2", "spread": "26.8"}, {"groupId": "OG001", "value": "406.0", "spread": "22.9"}]}]}, {"title": "Upper arm 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "345.8", "spread": "24.7"}, {"groupId": "OG001", "value": "455.2", "spread": "29.8"}]}]}, {"title": "Upper arm 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "429.4", "spread": "19.5"}, {"groupId": "OG001", "value": "366.1", "spread": "27.0"}]}]}, {"title": "Upper arm 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "532.6", "spread": "21.7"}, {"groupId": "OG001", "value": "471.6", "spread": "20.3"}]}]}]}, {"type": "SECONDARY", "title": "Apparent Volume of Distribution Based on the Terminal Phase (Vz/F)", "description": "To evaluate the Vz/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.", "populationDescription": "The PK analysis set consisted of all the subjects as defined for above endpoint. For Benralizumab 30mg AI, two subjects and for Benralizumab 30mg AFPS, three subjects were excluded from the PK analysis set.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liters", "timeFrame": "At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "87"}]}], "classes": [{"title": "Abdomen 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.56", "spread": "28.0"}, {"groupId": "OG001", "value": "11.30", "spread": "28.4"}]}]}, {"title": "Abdomen 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.50", "spread": "30.4"}, {"groupId": "OG001", "value": "12.79", "spread": "25.5"}]}]}, {"title": "Abdomen 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.26", "spread": "25.0"}, {"groupId": "OG001", "value": "12.22", "spread": "15.8"}]}]}, {"title": "Thigh 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.386", "spread": "18.2"}, {"groupId": "OG001", "value": "7.999", "spread": "15.5"}]}]}, {"title": "Thigh 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.32", "spread": "23.5"}, {"groupId": "OG001", "value": "8.596", "spread": "13.5"}]}]}, {"title": "Thigh 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.38", "spread": "20.2"}, {"groupId": "OG001", "value": "10.13", "spread": "21.0"}]}]}, {"title": "Upper arm 55.0 to 69.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.21", "spread": "21.2"}, {"groupId": "OG001", "value": "11.36", "spread": "17.7"}]}]}, {"title": "Upper arm 70.0 to 84.9 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.72", "spread": "23.6"}, {"groupId": "OG001", "value": "10.65", "spread": "18.7"}]}]}, {"title": "Upper arm 85.0 to 100.0 kg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.61", "spread": "23.0"}, {"groupId": "OG001", "value": "13.21", "spread": "32.9"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events", "description": "To evaluate safety and tolerability of Benralizumab", "populationDescription": "Safety set consisted of all subjects who received at least 1 dose of Benralizumab were included in the safety analysis for the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "At predose and 2 h postdose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "46"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Any AE leading to discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Antidrug Antibody (ADA) Status", "description": "To evaluate the immunogenicity of Benralizumab", "populationDescription": "Safety set consisted of all subjects who received at least 1 dose of Benralizumab were included in the safety analysis for the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "At predose (Day 1), Days 29 and 57", "groups": [{"id": "OG000", "title": "Benralizumab 30mg AI", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions."}, {"id": "OG001", "title": "Benralizumab 30mg AFPS", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"title": "ADA prevalence (positive at any visit)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "ADA incidence", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "At pre-dose and 2 h post-dose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57", "eventGroups": [{"id": "EG000", "title": "Benralizumab 30mg Autoinjector (AI)", "description": "All randomized subjects received 30mg Benralizumab by AI under fasted conditions.", "deathsNumAffected": 0, "deathsNumAtRisk": 90, "seriousNumAffected": 0, "seriousNumAtRisk": 90, "otherNumAffected": 50, "otherNumAtRisk": 90}, {"id": "EG001", "title": "Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)", "description": "All randomized subjects received 30mg Benralizumab by APFS under fasted conditions.", "deathsNumAffected": 0, "deathsNumAtRisk": 90, "seriousNumAffected": 0, "seriousNumAtRisk": 90, "otherNumAffected": 46, "otherNumAtRisk": 90}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 90}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Gingivitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Myringitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 90}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 90}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Nasal dryness", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 90}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Disturbance in attention", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Hypertonia", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 90}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Frequent bowel movements", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Muscle tightness", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Tendon discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Asthenia", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Discomfort", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Feeling hot", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Injection site hypersensitivity", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Pyrexia", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Sunburn", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Traumatic haematoma", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Skin fissures", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 90}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Listless", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Sleep disorder", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Excessive cerumen production", "organSystem": "Ear and labyrinth disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}, {"term": "Eye swelling", "organSystem": "Eye disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Ocular hyperaemia", "organSystem": "Eye disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Cardiovascular symptom", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Body temperature increased", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor."}, "pointOfContact": {"title": "AstraZeneca Clinical Study Information Center", "organization": "AstraZeneca Clinical Study Information Center", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-08-04", "uploadDate": "2019-05-14T08:47", "filename": "SAP_000.pdf", "size": 1413434}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-07-07", "uploadDate": "2019-05-14T08:48", "filename": "Prot_001.pdf", "size": 946694}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000029424", "term": "Pulmonary Disease, Chronic Obstructive"}], "ancestors": [{"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "asFound": "Pulmonary Disease", "relevance": "HIGH"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "asFound": "Obstructive Pulmonary Disease", "relevance": "HIGH"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "asFound": "Chronic Obstructive Pulmonary Disease", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "relevance": "LOW"}, {"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}